Human Papillomavirus (HPV)-vaccine produced in bacterial cells
Cervical cancer is one of the most common cancers in women worldwide and the incidence correlates with HPV (human Papillomavirus) infection. The two commercially available vaccines against HPV only protect against new infections (prophylactic vaccination), whereas existing infections are not cleared. The current technology provides a vaccine with the capability to function both as a prophylactic and a therapeutic vaccine. Moreover, it can be produced in bacterial cells, which makes production very cost-effective.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
